Edwards Lifesciences Corp (EW) concluded trading on Thursday at a closing price of $78.8, with 4.3 million shares of worth about $338.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.15% during that period and on July 10, 2025 the price saw a gain of about 2.09%. Currently the company’s common shares owned by public are about 586.20M shares, out of which, 574.69M shares are available for trading.
Stock saw a price change of 2.31% in past 5 days and over the past one month there was a price change of 3.20%. Year-to-date (YTD), EW shares are showing a performance of -14.20% which increased to 6.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $95.25 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.21 million. The stock is currently trading 3.40% above its 20-day simple moving average (SMA20), while that difference is up 3.31% for SMA50 and it goes to 9.43% higher than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 586.20M outstanding shares and institutions hold larger chunk of about 87.63% of that.
The stock has a current market capitalization of $46.22B and its 3Y-monthly beta is at 1.08. PE ratio of stock for trailing 12 months is 52.65, while it has posted earnings per share of $1.50 in the same period. Its PEG reads 6.15 and has Quick Ratio of 3.66 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 1.75% while standing at 1.90% over the month.
Stock’s fiscal year EPS is expected to rise by 1.70% while it is estimated to increase by 11.59% in next year. EPS is likely to grow at an annualized rate of 8.56% for next 5-years, compared to annual growth of -2.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on April 24, 2025 offering an Overweight rating for the stock and assigned a target price of $80 to it. Coverage by Stifel stated Edwards Lifesciences Corp (EW) stock as a Buy in their note to investors on January 30, 2025, suggesting a price target of $90 for the stock. Stock get an Equal-weight rating from Morgan Stanley on October 11, 2024.
